Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Long-Term Debt Repayments (2016 - 2021)

Lexaria Bioscience's Long-Term Debt Repayments history spans 2 years, with the latest figure at -$419.0 for Q3 2021.

  • For Q3 2021, Long-Term Debt Repayments changed N/A year-over-year to -$419.0; the TTM value through Aug 2022 reached -$419.0, down 100.44%, while the annual FY2021 figure was $22744.0, N/A changed from the prior year.
  • Long-Term Debt Repayments for Q3 2021 was -$419.0 at Lexaria Bioscience, down from $50000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at -$419.0 in Q3 2021 and bottomed at -$419.0 in Q3 2021.